Health / Gene Therapy
uniQure Faces FDA Uncertainty for Huntington's Disease Drug AMT-130
uniQure (QURE) faces regulatory uncertainty as the FDA questions the adequacy of existing data for its Huntington’s disease gene therapy, AMT-130, potentially delaying its approval timeline. This shift in the FDA's stance has significantly...